Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 11, Issue 5, 1996, Pages 438-447

  Pellegrin, Isabelle ^a   Legrand, Elisabeth ^b   Neau, Didier ^a   Bonot, Pascal ^a   Masquelier, Bernard ^a   Pellegrin, Jean Luc ^a   Ragnaud, Jean Marie ^a   Bernard, Noelle ^a   Fleury, Hervé J A ^a,c  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

HIV 1 provirus; HIV 1 RNA; Neutralizing antibodies; Primary HIV 1 infection

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; NEUTRALIZING ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; VIREMIA; VIRUS NEUTRALIZATION; VIRUS TITRATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0029981354     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199604150-00003     Document Type: Article

References (45)

1. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implication for therapy. Science 1993;262: 1011-8.
2. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
3. Kinloch-de-Loes S, De Saussure Ph, Saurat JH, Stadler H, Hirschel B, Perrin LH. Symptomatic primary human immunodeficiency virus type 1 infection: a review of 31 patients. Clin Infect Dis 1993;17:59-65.
4. Pantaleo G, Fauci AS. Tracking HIV during disease progres-sion. Curr Opin Immunol 1994;6:600-4.
5. Coombs RW, Collier AC, Allain JP, et al. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989;321:1626-31.
6. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in blood of infected persons. N Engl J Med 1989;321:1621-5.
7. Graziosi C, Pantaleo G, Butini L, et al. Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. Proc Natl Acad Sci USA 1993;90:6405-9.
8. Darr ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324: 961-4.
9. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-5.
10. Clark SJ, Saag MS, Decker WD, et al. High titer of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324:954-60.
11. Ariyoshi K, Harwood E, Chiengsong-Popov R, Weber J. Is clearance of HIV-1 viraemia at seroconversion mediated by neutralizing antibodies. Lancet 1992;340:1257-8.
12. Piatak M, Saag S, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-54.
13. Loveday C, Kaye S, Tenant Flowers M, et al. HIV RNA serum load and resistant viral genotypes during early zidovudine therapy. Lancet 1995;345:820-4.
14. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
15. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
16. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-9.
17. Mackewitz CE, Yang LC, Lifson JD, Levy JA. Non cytolytic CDS T-cell anti-HIV tesponses in primary HIV-1 infection. Lancet 1994;344:1671-3.
18. Albert J, Abrahamsson B, Nagy K, et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990; 4:107-12.
19. Tsang ML, Evans LA, McQueen P, et al. Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion. J Infect Dis 1994;170:1141-7.
20. Arendrup M, Nielsen C, Stig-Hansen JE, Pedersen C, Mathiesen L, Nielsen JO. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J Acquir Immune Defic Syndr 1992;5:303-7.
21. Moore J, Cao Y, Ho DD, Koup RA. Development of anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994;68:5142-55.
22. Zwart G, Back NK, Ramautarsing C, Valk M, Van der Hoek L. Frequent and early HIV-MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp 120 V3 domain. AIDS Res Hum Retroviruses 1994;10:245-51.
23. Sawyer LSW, Wrin MT, Crawford-Miksza L, et al. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cells in which the virus is propagated. J Virol 1994;68:1342-9.
24. Burton DR, Pyati J, Koduri R, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266:1024-7.
25. Cohen J. The HIV vaccine paradox. Science 1994;264: 1072-4.
26. Wrin T, Crawford L, Sawyer L, Weber P, Sheppard HW, Hanson CV. Neutralizing antibody response to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1994;7:211-9.
27. th International Conference on AIDS, Berlin 1993, Abstract PO-A210465.
28. Reed LJ, Muench HA. A simple method of estimating fifty per cent end points. Am J Hyg 1938;27:493-7.
29. Folks TM, Powell D, Lightfoote M, et al: Characterization of cloned Leu-3 cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med 1986; 164:280-90.
30. Ou C, Kwok S, Mitchell SW, et al. DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mono- nuclear cells. Science 1988;239:295-7.
31. Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988;239:487-91.
32. Japour AJ, Fiscus SA, Arduino JM, Mayers DL, Reicheldefer PS, Kuritzkes DR. Standardized microtiter assay for determination of syncytium inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Micro 1994;32:2291-4.
33. Chaix ML, Chappey C, Couillin I, Rozenbaum W, Levy JP, Saragosti S. Diversity of the V3 region of human immunodeficiency virus in Paris, France. AIDS 1993;7:1199-204.
34. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993;261:1179-81.
35. De Wolf F, Hogervorst E, Goudsmit J, et al. Syncytium- inducing and non-syncytium inducing capacity of HIV type 1 subtypes other than B: phenotypic and genotypic characteristics. AIDS Res Hum Retroviruses 1994;10:1387-400.
36. Murphy E, Korber B, Georges-Courbot MC, et al. Diversity of V3 region sequences of HIV types 1 from the Central African Republic. AIDS Res Hum Retroviruses 1993;9:997- 1006.
37. Luzuriaga K, McQuilken P, Alimenti A, Somasundaran M, Hesselton RA, Sullivan JL. Early viremia and immune responses in vertical human immunodeficiency virus type 1 infection. J Infect Dis 1993;167:108-13.
38. Battegay M, Moskophidis D, Waldner H, Brûndler MA, Fung-Leung WP, Mak TW, Hengartner H, Zinkernagel RM. Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells. J Immunol 1993; 151:5408-15.
39. Gras G, Richard Y, Roques P, Olivier R, Dormont D. Complement and virus-specific antibody dependent infection of normal B lymphocytes by human immunodeficiency virus type 1. Blood 1993;81:1808-18.
40. Pincus SH, Messer KG, Hu SL. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection. J Clin Invest 1994;93:140-6.
41. Pincus SH, Messer KG, Schartz DH, et al. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J Clin Invest 1993;91:1987-96.
42. Piatak M, Yang LC, Luk HC, et al. Viral dynamics in primary HIV-1 infection. Lancet 1993;341:1099.
43. Clementi M, Bagnarelli P, Menzo S, Valenza A, Manzin A, Varaldo PE. Clearance of HIV-1 viraemia after seroconversion. Lancet 1993;341:15-316.
44. Reimann KA, Tenner-Racz K, Racz P, et al. Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol 1994;68: 2362-70.
45. Fox CH, Tenner-Racz K, Racz P, Fripo A, Pizzo PA, Fauci AS. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type-1 RNA. J Infect Dis 1991;164: 1051-7.